{"organizations": [], "uuid": "9cdff39604935a75ca47cbcb42166c43500de033", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180215.html", "section_title": "Archive News &amp; Video for Thursday, 15 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-neurovive-decides-on-a-rights-issu/brief-neurovive-decides-on-a-rights-issue-for-continued-drug-development-idUSFWN1Q50F4", "country": "US", "domain_rank": 408, "title": "BRIEF-Neurovive Decides On A Rights Issue For Continued Drug Development", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.055, "site_type": "news", "published": "2018-02-15T15:43:00.000+02:00", "replies_count": 0, "uuid": "9cdff39604935a75ca47cbcb42166c43500de033"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-neurovive-decides-on-a-rights-issu/brief-neurovive-decides-on-a-rights-issue-for-continued-drug-development-idUSFWN1Q50F4", "ord_in_thread": 0, "title": "BRIEF-Neurovive Decides On A Rights Issue For Continued Drug Development", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 15 (Reuters) - NEUROVIVE PHARMACEUTICAL AB:\n* NEUROVIVE DECIDES ON A RIGHTS ISSUE FOR CONTINUED DRUG DEVELOPMENT\n* ‍TO ISSUE SHARES AND WARRANTS WITH PREFERENTIAL RIGHTS FOR EXISTING SHAREHOLDERS (“RIGHTS ISSUE”)​\n* ‍UPON FULL SUBSCRIPTION TO RIGHTS ISSUE, CO WILL RECEIVE ABOUT MSEK 78.5 BEFORE ISSUANCE COSTS.​\n* ‍IN FULL EXERCISE OF WARRANTS ISSUED IN RIGHTS ISSUE, CO WILL RECEIVE AN ADDITIONAL MSEK 37.3 BEFORE ISSUANCE COSTS.​\n* ‍SUBSCRIPTION PRICE IS SEK 8 PER UNIT, CORRESPONDING TO SEK 2 PER SHARE.​\n* ‍SUBSCRIPTION PERIOD RUNS FROM 10 APRIL - 24 APRIL 2018.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-15T15:43:00.000+02:00", "crawled": "2018-02-16T16:53:05.011+02:00", "highlightTitle": ""}